BioPharmSignal logoBioPharmSignal

Biotech News

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

PureTech Health (PRTC)PureTech HealthClinical readout

RNS Number: 0639Y PureTech Health PLC 07 October 2026 7 October 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo TM in Patients with Generalized Anxiety Disorder and Sleep Disturbance PureTech

Related news

PRTCPureTech Health2026-07-13 06:00 EST

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-06-09 06:00 EST

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

View all latest news

PureTech Health

Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea...

Recent company news

PRTCPureTech Health2026-10-07 17:00 EST

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

PRTCPureTech Health2026-09-22 06:00 EST

PureTech Health plc – Half-Year Report

PRTCPureTech Health2026-09-21 06:00 EST

PureTech Announces Successful End-of-Phase 1 Meeting with U.S . Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)

PRTCPureTech Health2026-09-09 17:00 EST

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

PRTCPureTech Health2026-09-04 06:00 EST

Notice of Half-Yearly Results

Stock data

Close
17.42 USD
Market cap
424.03M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States